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11 other countries had been included. COPD patients were recorded from a ter-
ritary care hospital in 2012. One-year costs were identified by applying cost data 
to medical information obtained by medical records. The cost analysis was based 
on cost of illness methodology. Costs included those for medications, laboratory 
and diagnostic tests, outpatient visits and hospital stays. Results: There were 612 
patients recruited. Patients were categorized by GOLD classification: 14.29% GOLDI, 
15.28% GOLDII, 38.21% GOLDIII, 32.23% GOLD IV. The median of hospitalization day 
was 9 days. 36.1% of patients were rehospitalized in 90 days. The mortality rate was 
3.1% because of exacerbation. The mean total direct costs was € 4,135.60 per patient 
in a year. The total annual cost was correlated with disease severity. Hospitalization 
contributed the major portion of cost and also correlated with disease severity. 
The average outpatient cost was € 98.62, hospitalization cost including interven-
tion was € 1,548.56, laboratory and diagnostic tests cost were € 103,03, comorbid-
ity and complication cost were € 1.493,88, medication cost with side effects were 
€ 903,59. ConClusions: There is a significant correlation between the cost of COPD 
and disease severity with hospitalization leading to disease exacerbation being a 
major contributor to cost. The keys to reducing health care costs lie beneath reducing 
the frequency of exacerbations and disease severity. As expected, the highest cost 
component was hospitalization, comorbidity and complication cost respectively.
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objeCtives: Ireland currently administers a universal BCG vaccination programme 
to infants. In order to assess the cost effectiveness of this programme, it is vital to 
have accurate cost estimates of the burden of tuberculosis (TB) illness in infants. The 
aim of the current study was to cost the diagnosis and treatment of an episode of the 
following health states; pulmonary TB, extrapulmonary TB, TB meningitis and latent 
TB, from the health care payer’s perspective. The cost of contact tracing per primary 
case of TB was also estimated. Methods: Decision trees were constructed to reflect 
typical episodes of care in the diagnosis and treatment of each health state. Resource 
use and unit cost data were applied to each node in the decision tree. The probabili-
ties of events occurring were derived from the literature and expert clinical opinion. 
Main costs included were inpatient medical/surgical costs, pediatrician outpatient 
appointments, medications, laboratory tests and x-rays. Each health state included a 
cost for a Directly Observed Therapy programme. Direct medical costs were calculated 
and the 2012 price year was used. Results: The direct medical costs of diagnosing 
and treating a case of pulmonary TB, extrapulmonary TB, TB meningitis and latent TB 
were estimated to be approximately € 8153, € 12224, € 15752 and € 894 respectively. The 
main drivers in the costs are the length of hospital stay and the number of pediatri-
cian visits. The cost of contact tracing per primary case of TB was estimated to be 
approximately € 4,248, which was based on a mean number of 9.4 contacts examined 
per primary TB case. ConClusions: To our knowledge this is the first investigation 
of costs associated with paediatric TB within the context of the Irish health care 
setting and will allow for a more robust estimation of the cost effectiveness of BCG 
vaccination programmes, which will benefit the health care payer.
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objeCtives: Comparative pharmacoeconomic assessment of COPD therapy of 
patients in GOLD 2-3 stages in Moscow health care system. Methods: Retrospective 
analysis of 130 cases during 1 year routine practice of patients with COPD in Moscow 
outpatients departments. Basic therapy strategies were obtaned: 1) monotherapy with 
indacaterol (14 pts. Low # of pts is because of the product was launched less than 
year ago); 2) monotherapy by tiotropium (33 pts), 3) fixed combination LABA + ICS 
(38 pts); 4) tiotropium plus fixed combination of LABA and ICS (45 pts). Cost of illness 
via calculation of direct medical costs on diagnostic, hospitalization, treatment of 
main disease and complications based on Federal Standards of COPD treatment and 
regional tariffs on cervices was estimated. Data on prices on medical products were 
obtained from State Register of medical products and www.aptechka.ru. Results: 
The most expencive strategy is management of group 4 - 86.5 KRUR/pt/year (1 Euro 
- 40 RUR) where 67% are costs on base drugs and 31% are hospitalization expenses. 
Usage of fixed combinations LABA + ICS is comparable with monotherapy by tiotro-
pium, total costs are 47 and 49 KRUR/pt/year accordingly. But if the reason of main part 
of the costs in group 3 is hospitalization due to exacerbation - 69%, for group 2 - 61% 
are expenditures on tiotropium. The most preferable is treatment of group 1 - 32847 
RUR/pt/year, where 55% - part on indacaterol, 42% - hospital treatment, 3% - urgent 
care. ConClusions: In spite of high price, indacaterol is the most economic prefer-
able product for basic COPD treatment of patients in GOLD 2-3 stages
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objeCtives: To predict health care costs in asthma using the EQ-5D health-related 
quality-of-life (HRQoL) index score. Methods: We extracted data from the 2000-
03 Medical Expenditure Panel Survey (MEPS) on adult respondents who had EQ-5D 
index scores. Asthma patients were identified using ICD-9 (= 493) and self-report on 
disease (n= 3,783). To account for non-random selection of positive spending, the 
chronic disease with a greater use of pain medications was RA/OA (44.8% vs 41.2%, 
P< 0.0001). COPD patients had more chronic use of short-acting opioids (24.2% vs. 
15.1%, P< 0.0001) and long-acting opioids (4.4% vs. 1.9%, P< 0.0001). Among COPD 
patients, those with chronic pain had higher mean annual direct cost [$24,261 vs. 
$10,390 (p< 0.0001)] which was largely attributable to increased hospitalizations 
(42.7% vs 25.4%, p< 0.0001). By comparison, the mean total medical cost for the 
matched cohort was $17,681 for those with chronic pain compared to $6,543 for 
individuals without chronic pain (P< 0.0001). Pain-related utilization was approxi-
mately 20% of COPD patients’ annual direct cost. ConClusions: COPD patients 
have increased prevalence of and utilization for chronic pain as compared to all 
other chronic illnesses except RA/OA. Individuals with chronic disease and chronic 
pain have more than double the cost of those without chronic pain, and this differ-
ence is even higher among individuals with COPD.
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objeCtives: To describe the direct costs to society of COPD per severity grades 
using the “Echantillon Generaliste de Beneficiaires”(EGB). EGB is a database 
which contains all health care resources used by a random 1/97 permanent sam-
ple of the French population covered by the national health care insurance sys-
tem. Methods: Several algorithms were developed to identify patients with COPD 
and to distinguish patients between four severity grades (1-4) based on health care 
consumption. These algorithms were based on age, rate and history of hospitaliza-
tions, treatments and tests received by the individuals. Exacerbations as well as their 
severity were identified through both antibiotics/corticosteroids drugs prescribed 
and hospitalizations. Total health care costs were calculated and a case-control 
approach was then used to estimate the cost of COPD. Exacerbations costs were 
calculated through a linear regression analysis including age and gender. Results: 
Based on the 10,715 COPD patients identified in the EGB, its prevalence was esti-
mated to 4.2% of the population beyond 40 years. The mean annual overall direct 
health care cost in this population was estimated to be € 9,382. Annual average costs 
were € 7,628; 10,770, 14,979 and 20,747 for severity grade 1-4 (severity data-base 
defined) respectively. The yearly cost of COPD itself was 5,516€ : 45.5% related to 
hospital care and 20.0% to pharmaceuticals (6.0% to long-acting bronchodilators). 
The average exacerbation cost was € 1,664 (SD: € 86.6). The global economic burden of 
COPD in France was therefore estimated over € 7 billions (4% of the national health 
care expense). ConClusions: Our study provides new solutions to estimate the 
burden of COPD in France using existing national databases. It confirms that COPD 
is associated with significant economic burden and the striking direct relationship 
between the cost of care and severity of the disease.
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objeCtives: Chronic Obstructive Pulmonary Disease (COPD) is a highly prevalent 
chronic inflammatory disease. Some COPD patients show a co-diagnosis of asthma 
(COPD-A). This real-life observational study assessed the frequency of exacerbations, 
the use of health care resources and their associated costs in patients with COPD only 
and COPD-A. Methods: Medical records from 6 Primary Care (PC) and one general 
hospital were reviewed and data from 2011 were collected from COPD and COPD-A 
patients aged 40 year or older who met specific inclusion/exclusion criteria. Main 
study variables were demography, co-morbidities, exacerbations and resources utili-
zation. Results: A total of 1210 COPD and 102 COPD-A, mean age (% male) 71.8 (85.5) 
and 71.2 (65.7) years, respectively, were included. Mean co-morbidity burden was simi-
lar in both groups with 7.9 and 7.8 diseases per patient. Most frequent co-morbidities 
(% in COPD; % in COPD-A) were dyslipidemia (63.0; 60.8) and arterial hypertension 
(59.5; 62.7) whereas the proportion of exacerbations (%) were 35.0 and 42.2, respec-
tively. Mean number of exacerbations per patient per year was 1.2 in COPD and 1.6 in 
COPD-A. The frequency of severe exacerbations (%) requiring hospitalizations was 
0.4 and 0.7, while those requiring oral corticosteroids was 24.4 and 33.0, respectively. 
Mean per patient, per year health care resources costs (Euro) were 2152.2 and 2207.5 
for PC-associated costs, and 1361.6 and 1754.3 for specialist care-associated costs, 
respectively. ConClusions: Exacerbations are frequent complications in COPD and 
COPD-A patients. Both groups show high proportion of co-morbidities and use of 
health care resources which were higher in the COPD-A group. Health care-related 
costs are high and are mainly related to hospitalizations and drug therapy.
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objeCtives: COPD has a major burden on Turkey’s health care system. It leads 
to high mortality, morbidity and frequent use of health care resources. This study 
determined the total direct health care costs for the management of COPD patients 
with differing degrees of disease severity. The study also aimed to find the key cost 
drivers in the management of COPD in Turkey. Methods: The methodology was 
based on a study conducted by European Respiratory Society in which Turkey and 
